Alnylam：2022年美国罕见病趋势报告：来自医疗保健支付者的观点-第三版（英文版）

Alnylam Pharmaceuticals, Inc., sponsored and developed this publication in partnership with their vendor, Guidehouse. Alnylam is a biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The Commercial Health Group at Guidehouse, a leading global consultancy that specializes in life sciences across both the commercial and public sectors, provided research services. Survey Development A survey was developed to capture paye